Cargando…
Improvement in pain severity category in clinical trials of pregabalin
BACKGROUND: Pregabalin is approved by the US Food and Drug Administration for the treatment of fibromyalgia (FM), diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), and neuropathic pain due to spinal cord injury (SCI). Approval was based on clinical trial data demonstrating statisti...
Autores principales: | Parsons, Bruce, Argoff, Charles E, Clair, Andrew, Emir, Birol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063480/ https://www.ncbi.nlm.nih.gov/pubmed/27785092 http://dx.doi.org/10.2147/JPR.S102696 |
Ejemplares similares
-
Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin
por: Parsons, Bruce, et al.
Publicado: (2015) -
Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
por: Freeman, Roy, et al.
Publicado: (2015) -
Pain relief and functional improvement in patients with neuropathic pain associated with spinal cord injury: an exploratory analysis of pregabalin clinical trials
por: Sadosky, Alesia, et al.
Publicado: (2016) -
A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain
por: Freynhagen, Rainer, et al.
Publicado: (2015) -
Integrating data from randomized controlled trials and observational studies to predict the response to pregabalin in patients with painful diabetic peripheral neuropathy
por: Alexander, Joe, et al.
Publicado: (2017)